← Back to headlines
Lilly to Acquire Engage Bio in Deal Worth Up to $202 Million
Pharmaceutical giant Eli Lilly has announced a deal to acquire Engage Bio, a company focused on non-viral genetic medicines, for up to $202 million. The acquisition aims to expand Lilly's portfolio in genetic medicine.
20 May, 14:38 — 20 May, 14:38
Sources
Showing 1 of 1 sources
